ClinicalTrials.gg
TerminatedNCT05647798Updated Jun 4, 2024

Intrapartum Glycemic Control in GDMA2

An interventional study of Blood sugar check every 2 hours and Blood sugar check every 4 hours in Pregnancy, Gestational Diabetes Mellitus, Class A2 and Neonatal Hypoglycemia, sponsored by Inova Health Care Services. Terminated at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Inova Health Care Services · Not applicable, Interventional, and Other

Why this study was terminated
Poor recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a randomized, parallel, controlled, non-inferiority trial to assess the impact of a tight versus a more liberalized intrapartum glycemic control in gestational diabetic mothers on neonatal glycemia. National guidelines for the management of intrapartum glucose in women with GDM are lacking. This is likely due to the scarcity of high-quality data on the topic.

Read the detailed description

Gestational diabetes mellitus (GDM) remains a common pregnancy complication, affecting 6-15% of pregnancies worldwide. The incidence of GDM is expected to continue its global upward trend in light of the growing obesity epidemic and delayed childbearing. GDM is associated with adverse short- and long-term maternal and offspring outcomes. Neonatal hypoglycemia, as a result of fetal hyperinsulinemia, occurs in up to 35% of pregnancies complicated by GDM with potential long-term neurodevelopmental sequelae. In that regard, significant emphasis has been placed on the prevention of neonatal hypoglycemia through optimal maternal glycemic control. Available data are conflicting as to the contribution of intrapartum glycemia to neonatal glycemia.

Moreover, national guidelines for the management of intrapartum glucose in women with GDM are lacking. This is likely due to a lack of high-quality data on the topic. As far as we are aware, only one single center randomized controlled trial has been published on the topic. That study's findings suggest that an approach to a more liberalized intrapartum glycemic management was not associated with a higher rate of neonatal hypoglycemia compared to a tight glycemic control regimen. We propose to replicate these findings in a different population at our institution. If this more relaxed approach to intrapartum glycemic management is confirmed to be safe to women and their babies, its clinical application has the potential to decrease the inconvenience of frequent finger pricks for our patients during labor and allow more efficient allocation of resources for the nursing staff on an already labor-intensive unit.

02

Conditions studied

  • Pregnancy
  • Gestational Diabetes Mellitus, Class A2
  • Neonatal Hypoglycemia

Browse trials for

Keywords

  • Intrapartum Glycemia
  • Labor
03

In context

Diabetes, Gestational

857 studies on the registry are indexed under Diabetes, Gestational; 199 are open to participants now.

This study's enrollment of 2 is below the median of 110 across 560 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Inova Health Care Services is the lead sponsor of 85 studies on the registry; 19 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women 18 years or older
  • Non-anomalous singleton gestation
  • Gestational diabetes type A2 diagnosed at 24 weeks' gestation or beyond
  • Planned vaginal delivery at term at Inova Fairfax Women's Hospital

Exclusion criteria

Exclusion Criteria:

  • Women \< 18 years
  • Fetus with major congenital malformations
  • Twin or higher order gestation
  • Pre-existing diabetes mellitus
  • Exposure to antenatal or any systemic steroids 14 days or less prior to delivery
  • Preterm delivery
  • Scheduled cesarean birth
  • Intrapartum cesarean birth prior to 4-5 cm of cervical dilatation
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    Usual care glycemic management arm

    Blood glucose will be checked every 2 hours during labor and glucose target will be 75-110 mg/dl

    Other: Blood sugar check every 2 hours

  • Active comparator
    More liberalized glycemic management arm

    Blood glucose will be checked every 4 hours during labor and glucose target will be 70-126 mg/dl

    Other: Blood sugar check every 4 hours

Interventions

  • OtherBlood sugar check every 2 hours

    Blood sugar check every 2 hours

  • OtherBlood sugar check every 4 hours

    Blood sugar check every 4 hours

06

What researchers measure

Primary outcomes

  1. Initial neonatal glucose post delivery

    First blood sugar recorded in newborn after delivery

    Time frame: first 2 hours of life

Secondary outcomes

  1. Neonatal hypoglycemia

    Blood glucose levels \< 40 mg/dl in the first 4 hours of life or \< 45 mg/dl beyond 4 hours of life

    Time frame: Birth of newborn until discharge to home or up to 7 days, whichever occurs first

  2. Neonatal hypoglycemia requiring neonatal intensive care unit (NICU)

    Blood glucose levels \< 40 mg/dl in the first 4 hours of life or \< 45 mg/dl beyond 4 hours of life that necessitates admission to the neonatal intensive care unit

    Time frame: Birth of newborn until discharge to home or up to 7 days, whichever occurs first

  3. Mean neonatal glucose within the first 24 hours post-delivery

    Average blood sugar in the newborn during the first 24 hours of life

    Time frame: First 24 hours after delivery

  4. Neonatal intensive care unit admission

    Any admission to the Neonatal Intensive Care Unit (NICU) within the first 72 hours of delivery

    Time frame: Birth of newborn until discharge to home or up to 7 days, whichever occurs first

  5. Neonatal intensive care unit length of stay

    Total time spent in the NICU from birth to discharge

    Time frame: Birth of newborn until discharge to home or up to 7 days, whichever occurs first

  6. Neonatal jaundice requiring phototherapy

    As determined by the Pediatrics provider

    Time frame: Birth of newborn until discharge to home or up to 7 days, whichever occurs first

  7. Mother's childbirth experience score

    Mother's experience of labor assessed by the Labor and Delivery Index (LADY-X) per Gartner et al.

    Time frame: Intrapartum

Other outcomes

  1. Number of intrapartum glycemia checks

    Total number of blood sugar checks during labor

    Time frame: Intrapartum

  2. Intrapartum glycemia mean

    Average maternal blood sugar during labor

    Time frame: Intrapartum

  3. Intrapartum insulin use

    Use of insulin during labor

    Time frame: Intrapartum

  4. Intrapartum insulin dose (total)

    Total insulin dose used during labor

    Time frame: Intrapartum

07

Study locations

2 sites
  • Inova Fairfax Medical campus
    Falls Church, Virginia 22042, United States
  • Inova Health Care Services
    Falls Church, Virginia 22042, United States
08

References and documents

Publications

  • McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019 Jul 11;5(1):47. doi: 10.1038/s41572-019-0098-8. PubMed 31296866 ↗
  • Lean SC, Derricott H, Jones RL, Heazell AEP. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One. 2017 Oct 17;12(10):e0186287. doi: 10.1371/journal.pone.0186287. eCollection 2017. PubMed 29040334 ↗
  • Schummers L, Hutcheon JA, Hacker MR, VanderWeele TJ, Williams PL, McElrath TF, Hernandez-Diaz S. Absolute risks of obstetric outcomes by maternal age at first birth: a population-based cohort. Epidemiology. 2018 May;29(3):379-387. doi: 10.1097/EDE.0000000000000818. PubMed 29517506 ↗
  • Lavery JA, Friedman AM, Keyes KM, Wright JD, Ananth CV. Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. BJOG. 2017 Apr;124(5):804-813. doi: 10.1111/1471-0528.14236. Epub 2016 Aug 11. PubMed 27510598 ↗
  • Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: Final Data for 2018. Natl Vital Stat Rep. 2019 Nov;68(13):1-47. PubMed 32501202 ↗
  • ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018 Feb;131(2):e49-e64. doi: 10.1097/AOG.0000000000002501. PubMed 29370047 ↗
  • Murray SR, Reynolds RM. Short- and long-term outcomes of gestational diabetes and its treatment on fetal development. Prenat Diagn. 2020 Aug;40(9):1085-1091. doi: 10.1002/pd.5768. Epub 2020 Jul 1. PubMed 32946125 ↗
  • Voormolen DN, de Wit L, van Rijn BB, DeVries JH, Heringa MP, Franx A, Groenendaal F, Lamain-de Ruiter M. Neonatal Hypoglycemia Following Diet-Controlled and Insulin-Treated Gestational Diabetes Mellitus. Diabetes Care. 2018 Jul;41(7):1385-1390. doi: 10.2337/dc18-0048. Epub 2018 Apr 13. PubMed 29654142 ↗
  • Dalgic N, Ergenekon E, Soysal S, Koc E, Atalay Y, Gucuyener K. Transient neonatal hypoglycemia--long-term effects on neurodevelopmental outcome. J Pediatr Endocrinol Metab. 2002 Mar;15(3):319-24. doi: 10.1515/jpem.2002.15.3.319. PubMed 11924935 ↗
  • Tam EW, Haeusslein LA, Bonifacio SL, Glass HC, Rogers EE, Jeremy RJ, Barkovich AJ, Ferriero DM. Hypoglycemia is associated with increased risk for brain injury and adverse neurodevelopmental outcome in neonates at risk for encephalopathy. J Pediatr. 2012 Jul;161(1):88-93. doi: 10.1016/j.jpeds.2011.12.047. Epub 2012 Feb 4. PubMed 22306045 ↗
  • Harris DL, Alsweiler JM, Ansell JM, Gamble GD, Thompson B, Wouldes TA, Yu TY, Harding JE; Children with Hypoglycaemia and their Later Development (CHYLD) Study Team. Outcome at 2 Years after Dextrose Gel Treatment for Neonatal Hypoglycemia: Follow-Up of a Randomized Trial. J Pediatr. 2016 Mar;170:54-9.e1-2. doi: 10.1016/j.jpeds.2015.10.066. Epub 2015 Nov 21. PubMed 26613985 ↗
  • Shah R, Harding J, Brown J, McKinlay C. Neonatal Glycaemia and Neurodevelopmental Outcomes: A Systematic Review and Meta-Analysis. Neonatology. 2019;115(2):116-126. doi: 10.1159/000492859. Epub 2018 Nov 8. PubMed 30408811 ↗
  • Yamamoto JM, Benham J, Mohammad K, Donovan LE, Wood S. Intrapartum glycaemic control and neonatal hypoglycaemia in pregnancies complicated by diabetes: a systematic review. Diabet Med. 2018 Feb;35(2):173-183. doi: 10.1111/dme.13546. PubMed 29117445 ↗
  • Yamamoto JM, Donovan LE, Mohammad K, Wood SL. Severe neonatal hypoglycaemia and intrapartum glycaemic control in pregnancies complicated by type 1, type 2 and gestational diabetes. Diabet Med. 2020 Jan;37(1):138-146. doi: 10.1111/dme.14137. Epub 2019 Oct 11. PubMed 31529717 ↗
  • Hamel MS, Kanno LM, Has P, Beninati MJ, Rouse DJ, Werner EF. Intrapartum Glucose Management in Women With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstet Gynecol. 2019 Jun;133(6):1171-1177. doi: 10.1097/AOG.0000000000003257. PubMed 31135731 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in May 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Dec 13, 2022
StartActual
May 22, 2023
Primary completionActual
May 15, 2024
CompletionActual
May 15, 2024
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05647798
Lead sponsor
Inova Health Care Services
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
May 22, 2023
Primary completion
May 15, 2024
Completion
May 15, 2024
Last update
Jun 4, 2024

Study contacts

Jean W Thermolice, MD
principal investigator · Inova Healthcare Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion